Detalhe da pesquisa
1.
Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.
Clin Pharmacol Drug Dev
; 7(3): 263-276, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28783871
2.
Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
J Med Chem
; 50(12): 2767-78, 2007 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-17488003
3.
Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.
J Clin Pharmacol
; 57(8): 988-996, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28398597
4.
Orally active purine-based inhibitors of the heat shock protein 90.
J Med Chem
; 49(2): 817-28, 2006 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-16420067
5.
7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors.
J Med Chem
; 49(17): 5352-62, 2006 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-16913725
6.
Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
J Med Chem
; 47(15): 3865-73, 2004 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15239664
7.
Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
Int J Cancer
; 120(4): 918-26, 2007 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17131314